Skip to main content

Table 1 Characteristics of the included cohort studies

From: Association between metabolic syndrome and prognosis of breast cancer: a meta-analysis of follow-up studies

Study Country Ethnicity Design Patient characteristics Sample size Mean age
years
MetS diagnosis MetS at baseline
n (%)
Follow-up duration
years
Outcomes reported Outcome validation Variables adjusted NOS
Pasanisi [15] Italy Caucasians PC Postmenopausal BC women 1 y after surgey, not undergoing chemotherapy 110 56.8 NCEP-ATP III 16 (14.5) 5.5 Recurrence (32) Hospital records Age, stage at diagnosis, HR status, current tamoxifen treatment, time between diagnosis and recruitment, serum testosterone 7
Oh [19] Korea Asians PC Newly diagnosed BC women after surgery 747 45.9 AHA/NHLBI 268 (35.9) 5.2 Recurrence (94) stratified by ER/PR status Hospital records Age, alcohol consumption, BMI, regional lymph node metastasis, tumor size, and chemotherapy 9
Calip [17] US Caucasians (90%) RC BC women 4 m after surgery 4216 62.2 NCEP-ATP III 1011 (23.9) 6.3 Recurrence (415), BC-related death (259), and all-cause death (1096) Hospital records Age, stage at diagnosis, HR status, primary treatment, race, menopausal status 8
Berrino [16] Italy Caucasians RC Stage I-III BC women after surgery 2092 51.4 IDF 419 (20.0) 2.8 Recurrence (94) stratified by ER status (164) Hospital records Age, education, stage at diagnosis, and the HR status 8
Fan [20] China Asians RC Stage I-III BC women 1249 49 AACE 206 (16.5) 6.6 Recurrence (265) and all-cause death (242) by HR status Hospital records Age, stage at diagnosis, surgery model, radiotherapy, and chemotherapy regimens 8
Muniz [21] The US Caucasians RC Stage I-II BC women with HR + , HER2- 534 56 NCEP-ATP III 117 (22.0) 4.4 Recurrence (24) Hospital records Age and stage at diagnosis 7
Simon [18] The US Caucasians (94%) PC Postmenopausal BC women 8641 62.9 AHA/NHLBI 423 (4.9) 11.3 BC-related death (619), and all-cause death (2181) Medical record review linkage to the National Death Index Age, stage at diagnosis, treatment, HR status, other comorbidities 8
Grybach [22] Ukraine Caucasians RC Stage I-III BC women 202 51.2 NCEP-ATP III 94 (46.5) 5 All-cause death (44) stratified by age Hospital records Age, stage at diagnosis, and HR status 7
Tong [23] China Asians RC HER2-positive BC women receiving neoadjuvant therapy 101 50.9 AHA/NHLBI 29 (28.7) 2.4 Recurrence (15) Hospital records Age, stage at diagnosis, HR status, and treatments 7
  1. PC prospective cohort, RC retrospective cohort, MetS metabolic syndrome, NOS the Newcastle–Ottawa Score, BC breast cancer, HER-2 human epidermal growth factor receptor-2, HR hormone receptor, ER estrogen receptor, PR progesterone receptor, NCEP-ATP III National Cholesterol Education Program’s Adults Treatment Panel III, IDF International Diabetes Federation, AHA American Heart Association, AACE American Association of Clinical Endocrinologists, NHLBI National Heart, Lung, and Blood Institute, BMI body mass index